Long-term effects of sonidegib on tumor burden: 30-month results from the phase 2 randomized bolt trial

Background: Sonidegib, a hedgehog pathway inhibitor (HPI), is approved in the United States and European Union for locally advanced basal cell carcinoma (laBCC) based on primary results from the BOLT trial (Migden, Lancet, 2015). Updated data from 30-months analysis demonstrated continued efficacy and manageable safety (Dummer ASCO 2016). Here we present 30-month tumor burden results, which have not previously been presented or published....